Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801) (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00886678
Recruitment Status : Unknown
Verified March 2010 by Zhejiang Cancer Hospital.
Recruitment status was:  Active, not recruiting
First Posted : April 23, 2009
Last Update Posted : February 24, 2011
Information provided by:
Zhejiang Cancer Hospital

Brief Summary:
Patients with inoperable Non-Small-Cell Lung Cancer will receive thoracic radiation therapy 66 Gy over 33 fractions,and concurrent with 2 cycles of chemotherapy with pemetrexed (500 mg/m2,d1,repeated every 3 weeks)and carboplatin (AUC=5,d1,repeated every 3 weeks).

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: pemetrexed Drug: carboplatin Radiation: thoracic radiation Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 63 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer
Study Start Date : July 2008
Estimated Primary Completion Date : July 2010
Estimated Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: 1
patients receiving pemetrexed, carboplatin and radiation therapy.
Drug: pemetrexed
500 mg/m2, IV, q 21 days x 2 cycles

Drug: carboplatin
AUC=5,IV,q 21 days x 2 cycles

Radiation: thoracic radiation
66 Gy over 33 fractions

Primary Outcome Measures :
  1. tumor response rate [ Time Frame: Tumor assessments after completion of chemoradiotherapy and every 2 months ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: baseline to date of death from any cause ]
  2. time to progressive disease [ Time Frame: baseline to measured progressive disease ]
  3. the safety profile [ Time Frame: every cycle ]
  4. site of first failure in patients who develop progressive disease [ Time Frame: baseline to measured progressive disease ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven non-small cell lung cancer (non-squamous cell carcinoma)
  • Presence of measurable disease by RECIST
  • Inoperable stage IIIA or IIIB
  • ECOG performance status 0-1
  • No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
  • Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital.

Exclusion Criteria:

  • Carcinoid tumor, small cell carcinoma of lung
  • Patients with any distant metastasis
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix Any other morbidity or situation with contraindication for chemotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment)
  • Pregnant or lactating women, women who has not taken test of pregnancy (within 14 days before the first administration) and pregnant women
  • Women and men of childbearing potential who have no willing of employing adequate contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00886678

Layout table for location information
China, Zhejiang
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Sponsors and Collaborators
Zhejiang Cancer Hospital
Layout table for investigator information
Principal Investigator: Ma Sheng lin, MD Zhejiang Cancer Hospital
Layout table for additonal information
Responsible Party: Ma Shenglin, Xu Yaping, Zhejiang Cancer Hospital Identifier: NCT00886678    
Other Study ID Numbers: ZhejiangCH01
First Posted: April 23, 2009    Key Record Dates
Last Update Posted: February 24, 2011
Last Verified: March 2010
Keywords provided by Zhejiang Cancer Hospital:
Non-Small Cell Lung Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors